title: Effect of pretransplantation body mass index on allograft function and patient survival after renal transplantation.
abstract: We evaluated the effects of pretransplantation recipient body mass index (BMI) on allograft survival and on kidney function. Kidney transplant recipients were grouped according to their pretransplantation BMIs: Group I (BMI<18.5 kg/m2; n=10); Group II (BMI 18.5-24.9 kg/m2; n=62); Group III (BMI 25.0-29.9 kg/m2; n=47); and Group IV (BMI>30.0 kg/m2; n=16). Excellent 1-year patient and graft survival rates were observed in all groups. Increased BMI was associated with increased hypertension and longer hospital stays. The incidence of acute rejection episodes, slow graft function, and delayed graft function, as well as the need for antithymocyte globulin Fresenius (ATG-F) rescue therapy were comparable between the 4 patient groups. The 1-year glomerular filtration rate was markedly different between the 4 patient groups. The 1-year posttransplantation glucose level was higher among obese patients compared with the other groups. A multivariate regression analysis confirmed the association of a higher 1-year GFR with obesity (BMI>30.0 kg/m2). Overweight and obese recipients showed excellent long-term patient and graft survival rates. Accordingly, denying patients renal transplantation because of obesity may not be justified.
authors.affiliation: Department of Surgery, Sacre'-Coeur Hospital, Baabda-Hazmieh, Lebanon.
authors.forename: M M
authors.initials: MM
authors.lastname: Abou-Jaoude
authors.forename: N
authors.initials: N
authors.lastname: Nawfal
authors.forename: R
authors.initials: R
authors.lastname: Najm
authors.forename: M
authors.initials: M
authors.lastname: Honeidi
authors.forename: J
authors.initials: J
authors.lastname: Shaheen
authors.forename: W Y
authors.initials: WY
authors.lastname: Almawi
mesh_terms: D000367:Age Factors; D015992:Body Mass Index; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000276:immunology / Q000502:physiology; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007239:Infections / Q000453:epidemiology; D007431:Intraoperative Complications / Q000453:epidemiology; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D007902:Length of Stay; D008297:Male; D015999:Multivariate Analysis; D009765:Obesity / Q000150:complications / Q000453:epidemiology; D011300:Preoperative Care; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents